A Phase 4 interventional study of desloratadine and levocetirizine in Hypersensitivity, sponsored by Organon and Co. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-09.
Sponsored by Organon and Co · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single center study in subjects with positive histamine skin prick test and a positive RadioAllergoSorbent Test (RAST) (class > 2) to one of the tested standardized allergenic extracts: tree pollen, cat dander, house dust mite, or a mixture of five grass pollens. Subjects will be randomized to desloratadine 5 mg once daily, levocetirizine 5mg once daily, or placebo once daily for 8 days of treatment followed by 11 days of skin testing after discontinuation of the antihistamine treatment phase. The duration of the suppressive effects of desloratadine on cutaneous allergen-induced wheal and flare responses after discontinuation of a one-week treatment will be established.
1,058 studies on the registry are indexed under Hypersensitivity; 152 are open to participants now.
This study's enrollment of 36 is below the median of 73 across 692 interventional studies indexed under Hypersensitivity.
Browse Hypersensitivity studies →Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Medications Prohibited During the Trial and Washout Period Prior to Visit 1
Cromolyn/Lodoxamide/Nedocromil
Antihistamines
Decongestants
Tetracyclic antidepressants (eg, maprotiline, mirtazapine), 30 days
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).
Drug: desloratadine · Drug: Levocetirizine placebo capsule
Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).
Drug: levocetirizine · Drug: Desloratadine placebo tablet
Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).
Drug: Desloratadine placebo tablet · Drug: Levocetirizine placebo capsule
5 mg tablet once daily
5 mg capsule once daily
once daily
once daily
Duration of Suppressive Effect of Desloratadine After Discontinuation of a 1-week Treatment
The number of days after treatment discontinuation until a measurable wheal and flare response.
Time frame: Starting at Day 8
| Milestone | Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule | Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule | Desloratadine Placebo Tablet + Levocetirizine Placebo Capsule |
|---|---|---|---|
| Started | 12 | 12 | 12 |
| Completed | 12 | 12 | 12 |
| Not completed | 0 | 0 | 0 |
The number of days after treatment discontinuation until a measurable wheal and flare response.
| Days | Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule | Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule | Desloratadine Placebo Tablet + Levocetirizine Placebo Capsule |
|---|---|---|---|
| Duration of Suppressive Effect of Desloratadine After Discontinuation of a 1-week Treatment | 5 ± 1.65 | 4 ± 1.60 | NA ± NA |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule | — | 0/12 (0%) | 5/12 (41.7%) |
| Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule | — | 0/12 (0%) | 4/12 (33.3%) |
| Desloratadine Placebo Tablet + Levocetirizine Placebo Capsule | — | 0/12 (0%) | 1/12 (8.3%) |
| Event | Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule | Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule | Desloratadine Placebo Tablet + Levocetirizine Placebo Capsule |
|---|---|---|---|
| SomnolenceNervous system disorders | 1/12 | 2/12 | 0/12 |
| Abdominal Pain UpperGastrointestinal disorders | 1/12 | 0/12 | 0/12 |
| Dry MouthGastrointestinal disorders | 0/12 | 1/12 | 0/12 |
| NauseaGastrointestinal disorders | 1/12 | 1/12 | 0/12 |
| VomitingGastrointestinal disorders | 0/12 | 1/12 | 0/12 |
| AstheniaGeneral disorders | 1/12 | 1/12 | 0/12 |
| RhinitisInfections and infestations | 0/12 | 1/12 | 1/12 |
| Muscle ContractureMusculoskeletal and connective tissue disorders | 0/12 | 1/12 | 0/12 |
| HeadacheNervous system disorders | 1/12 | 0/12 | 0/12 |
| InsomniaPsychiatric disorders | 0/12 | 1/12 | 0/12 |
| Age, Continuous(years) | Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule | Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule | Desloratadine Placebo Tablet + Levocetirizine Placebo Capsule | Total |
|---|---|---|---|---|
| Mean | 23.42 ± 4.91 | 28.33 ± 8.69 | 28.83 ± 11.55 | 26.86 ± 8.91 |
| Sex: Female, Male(Participants) | Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule | Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule | Desloratadine Placebo Tablet + Levocetirizine Placebo Capsule | Total |
|---|---|---|---|---|
| Female | 5 | 8 | 5 | 18 |
| Male | 7 | 4 | 7 | 18 |
No study locations are listed for this record.
The record gives a start of Feb 2006, a primary completion of May 2006 and a completion of May 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2010, 4 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Desloratadine